Skip to main content

Opioid Overdose Reversal Agents (OK SPA 24-0003 & APA WF # 23-28)

The proposed State Plan Amendment and rule revisions will allow for coverage of new opioid overdose reversal agents as they come to market. Currently, cost-sharing and prescription limit exemptions refer to "Naloxone", this will be updated with broader language to encompass other opioid overdose reversal agents to allow for coverage of these products as appropriate.

Please view the draft SPA pages OK SPA 24-0003 and circulation documents APA WF # 23-28 and submit feedback via the comment box.

Tribal Consultation: 10/31/2023

60-day Tribal Consultation Period: 10/27/2023 – 12/26/2023

Circulation Date: 10/27/2023

Comment Due Date: 11/26/2023

Submit a Comment

Couldn't verify captcha, Please refresh the page and try again.

After you submit your comment, you should be re-directed to a confirmation page. If you are not, please submit your comment through e-mail to federal.authorities@okhca.org.

Please note that all comments must be reviewed and approved prior to posting. Approved comments will be posted Monday through Friday between the hours of 7:30 a.m. – 4 p.m. Any comments received after 4 p.m. will be posted on the following business day.

Comments

No comments.

Last Modified on Jan 24, 2024
Back to top

Oklahoma Health Care Authority

4345 N Lincoln Blvd

Oklahoma City, OK 73105

Contact Us

The Oklahoma Health Care Authority collects the personally identifiable data submitted and received in regard to applications for services, renewals, appeals, provision of health care and processing of claims. This data is treated as confidential and is stored securely in accordance with applicable law and regulations. OHCA may share this personally identifiable data with its authorized business associates, government agencies with jurisdiction over the OHCA, or as otherwise required or permitted by applicable law.